Why the study?
Does dapagliflozin improve left ventricular diastolic function in patients with type 2 diabetes mellitus and stable heart failure?
Does dapagliflozin improve left ventricular diastolic function in patients with type 2 diabetes mellitus and stable heart failure?
Dapagliflozin 5 mg/day significantly improved echocardiographic parameters of left ventricular diastolic function (E/e', LAVI, LVMI) over 6 months in patients with type 2 diabetes and stable heart failure.
No takes yet. Share an insight, caveat, or question.
May support diastolic improvement with dapagliflozin in T2DM and stable HF; hypothesis-generating and requires RCTs before practice change.
Soga et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: